Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 31, 2000

View Archived Issues

Combined vasodilating and beta-blocking properties of new NO donor PF-9404C

Oxford BioMedica and IDM to collaborate on cell-based therapies

Millennium continues to "move downstream" during Q4 and year-end 1999

Immunex highlights year-end 1999 progress

NYU School of Medicine and P&U establish anticancer drug discovery collaboration

FDA approves more than 140 new drugs and devices in 1999

Progenics receives payment from BMS for cancer vaccine collaboration

Access to begin phase II trial of OraRinse for treatment and prevention of mucositis

Insmed receives funding for clinical programs

Amine compounds as 5-HT reuptake inhibitors emerge from Lilly R&D

Potent, subtype-selective NMDA antagonists jointly developed at CoCensys & Warner-Lambert

Synthetic thyromimetics useful for hyperthyroidism, cardiac arrhythmias

ADIR's new MMP and TNF-alpha production inhibitors described in recent patent

Another series of substituted carbapenems from Merck useful against resistant pathogens

CRF antagonists with pyrazolo[1,5-a]triazine structure in development at DuPont

IC-351 improves erectile response to visual stimulation in men with mild to moderate ED

RCT patents GH treatment regimen for rheumatoid arthritis

Bayer presents new candidate treatment for ED at ESIR

Application of Ariad's Dimerizer Drug technology covered by two U.S. patents

Biomira reports survival data for therapeutic cancer vaccine

Boehringer Ingelheim adds structurally novel HIV protease inhibitor to R&D portfolio

OPC-41061 + furosemide: additive diuretic effect + beneficial effect on electrolytes

Immtech dication compounds show potential as small-molecule regulators of gene function

Servier compound S-18327 displays distinctive and promising profile as schizophrenia Rx

ML Laboratories updates AIDS products

Combined ACE inhibition and AT1 blockade does not improve coronary hemodynamics in post-MI rats